Moderna’s concerns about omicron outlook spark market slump

Michelle Fay Cortez
Bloomberg

Moderna Inc.’s top executives reiterated that the omicron variant’s many mutations suggest new vaccines will be needed, triggering a drop in financial markets. 

“The number of mutations on this virus are surprising,” co-founder Noubar Afeyan said in a Bloomberg Television interview.  “We have to take it for the serious threat that it poses.” 

Already a subscriber? Sign In

Subscribe to keep reading

Get unlimited digital access for only $1 for 6 months
Subscribe Now